News Summary

• AAVantgarde Bio is a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases.
• The company’s lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B.
• AAVB-039 and AAVb-081 are investigational, dual AAV gene therapies designed to address the root genetic causes of these diseases.
• There have been no drug-related serious adverse events or dose-limiting toxicities to date.
• Ocular inflammation has been infrequent, and reversible with steroid treatment.